Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
European Journal of Ophthalmology|October 18, 2022
Incidence of adverse events after loading phase of the brolucizumab therapy of neovascular AMD: Real-life evidence in the Czech RepublicAlexandr Stepanov, Jan Studnicka, Miroslav Veith, et al.
Journal of Ophthalmology|May 27, 2020
Results of Ranibizumab Treatment of the Myopic Choroidal Neovascular Membrane according to the Axial Length of the EyeAlexandr Stepanov, Martin Pencak, Jan Nemcansky, et al.
European Journal of Ophthalmology|November 17, 2020
Two-year results of a combined regimen of aflibercept treatment in three types of choroidal neovascular membrane in the wet form of age-related macular degeneration: Real-life evidence in the Czech RepublicAlexandr Stepanov, Jan Nemcansky, Miroslav Veith, et al.
Biomedical Papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia|April 29, 2015
The efficacy of ranibizumab treatment in clinical practice in patients with the wet form of age-related macular degeneration. The results of the Czech National RegistryOldrich Chrapek, Jiri Jarkovsky, Jan Studnicka, et al.
Neuro Endocrinology Letters|July 31, 2023
Widened retinal arteriolar and venular diameters are not an endophenotype of schizophrenia: A one-time cross-sectional studyLadislav Hosak, Evgenii Sadykov, Jana Zapletalova, et al.
Biomedical Papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia|December 4, 2012
Effects of treatment change in patients with neovascular age-related macular degeneration; results from the Czech National RegistryJan Studnicka, Eva Rencova, Pavel Rozsival, et al.
Scientific Reports|November 21, 2024
Soluble endoglin as a biomarker of successful rheopheresis treatment in patients with age-related macular degenerationVladimir Blaha, Jana Urbankova Rathouska, Hana Langrova, et al.
JAMA Ophthalmology|November 19, 2020
Efficacy and Safety of a Proposed Ranibizumab Biosimilar Product vs a Reference Ranibizumab Product for Patients With Neovascular Age-Related Macular Degeneration: A Randomized Clinical TrialSe Joon Woo, Miroslav Veith, Jan Hamouz, et al.
JAMA Ophthalmology|June 8, 2023
Efficacy and Safety of the Aflibercept Biosimilar SB15 in Neovascular Age-Related Macular Degeneration: A Phase 3 Randomized Clinical TrialSe Joon Woo, Mario Bradvica, Attila Vajas, et al.
Pageof 2